Spadin Analogue
Evidence Grade E — Very limited evidence. 1 published studies. 0 registered clinical trials.
PE-22-28 is a synthetic peptide that targets a specific potassium channel (TREK-1) in the brain, derived from a natural regulatory peptide called spadin. All research comes from a single French laboratory. No human clinical trials have been conducted. It has no regulatory approval.
1 published studies: 0 human, 0 animal, 1 in-vitro, 0 reviews
PE-22-28 has no marketing authorisation. No human clinical trials have been conducted. The preclinical evidence comes predominantly from a single research group at a French institution.
Animal studies have used the forced swim test — a behavioural assay whose predictive validity for human outcomes is debated in the scientific community. No human pharmacokinetic, safety, or efficacy data exist. Products available through unregulated channels lack pharmaceutical quality assurance.
Research in animal models suggests PE-22-28 blocks the TREK-1 potassium channel with high selectivity at very low concentrations. TREK-1 channels are expressed in brain regions associated with mood regulation. These observations come from mouse behavioural studies and electrophysiology experiments conducted by a single laboratory.
Research suggests rigorous laboratory electrophysiology and multiple animal behavioural studies support the mechanism, with the TREK-1 target validated by human genetic data. The compound shows high selectivity and potency at very low concentrations. However, no human data of any kind exist, limited independent replication has been published outside the originating group, and poor oral bioavailability limits practical use. The behavioural tests used in animals (such as the forced swim test) have debated predictive validity for human outcomes. Products from unregulated channels lack pharmaceutical quality assurance.
No trials registered on ClinicalTrials.gov for this compound.
The information on this page is provided for educational and research reference purposes only. This is not medical advice. Always consult a qualified healthcare professional before making any health-related decisions.
Pinealon has no marketing authorisation from any major regulatory agency. No controlled human clinical trials have been conducted. The evidence base consists of in vitro cell studies and animal experiments published primarily by the originating research group. As with other Khavinson bioregulator peptides, the proposed mechanisms and the underlying theoretical framework have not been evaluated through conventional Western regulatory processes. Products available through unregulated channels lack pharmaceutical quality assurance.
Selank is approved in Russia for anxiety-related conditions. It has not been approved by the FDA, EMA, or other major Western regulatory agencies. The key clinical study (62 patients) compared Selank to a benzodiazepine in generalised anxiety disorder and reported comparable effects. Published clinical studies are predominantly Russian and have not undergone Western regulatory review. The evidence base does not meet FDA or EMA approval standards. Its regulatory status is limited to Russia and certain former Soviet states.
Semax is approved in Russia for stroke recovery and cognitive conditions. It has not been approved by the FDA, EMA, or other major Western regulatory agencies, and the clinical evidence base has not undergone Western regulatory review. Published clinical studies are predominantly Russian. The largest published study (110 stroke patients) reported correlations between treatment and BDNF levels. The evidence does not meet the standards typically required for FDA or EMA approval. Its regulatory status is limited to Russia and certain former Soviet states.
